Literature DB >> 32057906

Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats.

Daisuke Inoue1, Tomoyuki Furubayashi2, Akiko Tanaka3, Toshiyasu Sakane4, Kiyohiko Sugano5.   

Abstract

For establishing a precise system for predicting in vivo bioavailability following intranasal (IN) administration, the relationships among membrane permeability of drugs across Calu-3 cells, in situ nasal mucosal drug permeation rate, and in vivo drug absorption following IN administration were quantified. The membrane permeability coefficient (Papp) was determined for sixteen model drugs by in vitro permeation studies in Calu-3 cells. The drug permeation rate constant through the nasal mucosa (kn) was calculated from the in situ nasal perfusion of the drug solutions in rats. Bioavailability following IN administration of six model drugs with different membrane permeabilities were determined by in vivo drug absorption studies in rats. The correlations among in vitro membrane permeability properties, in situ nasal mucosal drug permeation rate, and in vivo drug absorption following IN administration, were assessed. The significant correlation between the in vitro Calu-3 cell permeability and nasal mucosal drug permeation rate (r2=0.812, p<0.001) indicated that nasal mucosal drug permeability is estimable from in vitro membrane permeability. Furthermore, bioavailability following IN administration significantly correlated with the in vitro Papp across Calu-3 cells (r2=0.984, p<0.001), suggesting that in vivo drug absorption following IN administration can be predicted from in vitro Calu-3 membrane permeability.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Calu-3 cell line; Nasal absorption; PK modeling; bioavailability; in vitro-in vivo correlation; intranasal administration; mucosal absorption; nasal formulation; pharmacokinetics

Year:  2020        PMID: 32057906     DOI: 10.1016/j.ejpb.2020.02.004

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

1.  Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine.

Authors:  Yingchong Chen; Yuling Liu; Jin Xie; Qin Zheng; Pengfei Yue; Liru Chen; Pengyi Hu; Ming Yang
Journal:  Int J Nanomedicine       Date:  2020-12-23

2.  Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations.

Authors:  Nadica Sibinovska; Simon Žakelj; Jurij Trontelj; Katja Kristan
Journal:  Pharmaceutics       Date:  2022-02-06       Impact factor: 6.321

3.  Formulation and In Vitro Characterization of a Vacuum-Dried Drug-Polymer Thin Film for Intranasal Application.

Authors:  Daisuke Inoue; Ayari Yamashita; Hideto To
Journal:  Polymers (Basel)       Date:  2022-07-21       Impact factor: 4.967

4.  A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies.

Authors:  Laura Nižić Nodilo; Ivo Ugrina; Drago Špoljarić; Daniela Amidžić Klarić; Cvijeta Jakobušić Brala; Mirna Perkušić; Ivan Pepić; Jasmina Lovrić; Vesna Saršon; Maša Safundžić Kučuk; Dijana Zadravec; Livije Kalogjera; Anita Hafner
Journal:  Pharmaceutics       Date:  2021-05-26       Impact factor: 6.321

5.  Membrane thickness, lipid phase and sterol type are determining factors in the permeability of membranes to small solutes.

Authors:  Jacopo Frallicciardi; Josef Melcr; Pareskevi Siginou; Siewert J Marrink; Bert Poolman
Journal:  Nat Commun       Date:  2022-03-25       Impact factor: 17.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.